MAPT and Parkinson disease: An increase in Fe in the SNpc is well-established in PD [16, 17, 29–31], and metal modulation with iodochlorhydroxyquin (clioquinol) has shown therapeutic benefit by reducing Fe, preventing neurodegeneration, and rescuing the motor impairment in aged tau−/− mice [23].